Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Satellos was founded on the discovery that dysregulated muscle stem-cell polarity - a process that balances replenishment of muscle stem cells and production of specialized tissue cells- can lead to the inability of the body to properly repair and regenerate muscle throughout life. Satellos' lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. Accordingly, Satellos applies its proprietary discovery platform, MyoReGenX, to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated.

Therapeutics

Life Sciences

Satellos Bioscience Inc.

Frank Gleeson

Adam Mostafa

Ryan Mitchell

Elizabeth Williams

Philip Lambert

Michael Rudnicki

Courtney Wells

��

Satellos Bioscience Inc.

Org chart

Teams

Similar companies

��������

Satellos Bioscience Inc.

Org chart

Teams

Similar companies

��